Basket cover image
16 handpicked stocks

Supply Chain Shift: The Southeast Asia Advantage

Chinese exporters accelerated shipments to the U.S. ahead of potential tariffs, strategically rerouting goods through Southeast Asia. This shift creates an investment opportunity in the logistics and manufacturing firms in these intermediary countries that are facilitating this new trade flow.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at अगस्त 7

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

LSH

LAKESIDE HOLDING LTD.

LSH

Current price

$1.03

GXO

GXO Logistics, Inc.

GXO

Current price

$53.34

SE

Sea Limited

SE

Current price

$179.25

About This Group of Stocks

1

Our Expert Thinking

Chinese exporters are strategically accelerating shipments and rerouting goods through Southeast Asia to avoid potential U.S. tariffs. This creates a significant opportunity for logistics, manufacturing, and technology companies in these intermediary countries that are becoming critical hubs in the new global trade landscape.

2

What You Need to Know

This group focuses on companies providing essential services like transportation, warehousing, final assembly, and digital commerce platforms. These businesses are positioned to benefit from increased trade volumes as supply chains permanently shift through Southeast Asian routes to circumvent direct tariffs.

3

Why These Stocks

These companies were handpicked by professional analysts as the key enablers of trade rerouting. They represent the backbone of the altered supply chain, offering exposure to sustained growth from increased goods volumes passing through their jurisdictions in this evolving trade dynamic.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+20.57%

Group Performance Snapshot

20.57%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 20.57% over the next year.

14 of 15

Stocks Rated Buy by Analysts

14 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🚢

Trade Route Revolution

A massive shift in global supply chains is happening right now, with billions of pounds worth of goods being rerouted through Southeast Asia. These companies are at the centre of this historic trade transformation.

📈

Growth from Disruption

When trade patterns change this dramatically, the companies that facilitate the new routes often see sustained growth. These logistics and manufacturing firms are positioned to benefit from increased volumes for years to come.

🎯

Strategic Positioning

Professional analysts identified these companies as the key enablers of the new trade landscape. They're not just benefiting from current shifts but are building the infrastructure for tomorrow's global commerce.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.